| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 | Dec'17 | Sep'17 | Jun'17 | Mar'17 | Sep'16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenues: | |||||||||||||
Grant revenue | |||||||||||||
11,026 | 13,405 | 12,163 | 8,350 | 6,724 | 3,966 | 0 | 0 | 0 | - | - | - | - | - |
Collaboration revenue | |||||||||||||
1,104 | 4,742 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - |
Total revenues | |||||||||||||
12,130 | 18,147 | 16,209 | 12,224 | 10,531 | 3,966 | 0 | 0 | 0 | - | 0 | 0 | - | - |
Grant revenue | |||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | 0 | - |
Operating expenses: | |||||||||||||
Research and development | |||||||||||||
76,685 | 65,775 | 49,174 | 39,138 | 34,486 | 33,885 | 37,261 | 35,712 | 35,795 | 32,869 | 26,371 | 0 | 0 | 0 |
General and administrative | |||||||||||||
15,786 | 15,588 | 15,452 | 14,453 | 13,731 | 12,887 | 11,728 | 12,247 | 12,144 | 10,840 | 10,259 | 0 | 0 | 0 |
Total operating expenses | |||||||||||||
92,471 | 81,363 | 64,626 | 53,591 | 48,217 | 46,772 | 48,989 | 47,959 | 47,939 | 43,709 | 36,630 | 0 | 0 | 0 |
Loss from operations | |||||||||||||
-80,341 | -63,216 | -48,417 | -41,367 | -37,686 | -42,806 | -45,722 | -44,753 | -44,947 | -41,730 | -35,644 | 0 | 0 | 0 |
Other income (expense): | |||||||||||||
Interest income | |||||||||||||
0 | - | - | - | 0 | - | - | - | - | - | - | - | - | - |
Change in fair value of derivative liabilities | |||||||||||||
- | - | - | - | - | - | - | - | - | 1,541 | -1,543 | 0 | 0 | 0 |
Interest income and other income (expense), net | |||||||||||||
- | - | 1,879 | 2,083 | - | - | 797 | 449 | 486 | 303 | 0 | 0 | 0 | - |
Other income (expense), net | |||||||||||||
-319 | 740 | 539 | 743 | 256 | 43 | 791 | 441 | 828 | 1,844 | 1,708 | 0 | 0 | 0 |
Total other income (expense), net | |||||||||||||
0 | - | - | - | 0 | - | - | - | - | - | - | - | - | - |
Net loss | |||||||||||||
-79,111 | -60,925 | -46,538 | -39,284 | -36,090 | -41,662 | -44,931 | -44,312 | -44,119 | -39,886 | -33,936 | 0 | 0 | 0 |
Less: Net loss attributable to non-controlling interest | |||||||||||||
- | - | - | - | - | - | - | - | - | -1,143 | -2,739 | 0 | 0 | 0 |
Net loss attributable to Spero Therapeutics, Inc. | |||||||||||||
- | - | - | - | - | - | - | - | - | -38,743 | -31,197 | 0 | 0 | 0 |
Cumulative dividends on redeemable convertible preferred shares | |||||||||||||
- | - | - | - | - | - | - | - | - | 6,146 | 6,229 | 0 | 0 | 0 |
Accretion of redeemable bridge units and redeemable convertible preferred shares to redemption value | |||||||||||||
- | - | - | - | - | - | - | - | - | 1,208 | 1,311 | 0 | 0 | 0 |
Net loss attributable to common shareholders of Spero Therapeutics, Inc. | |||||||||||||
- | - | - | - | - | - | - | - | - | -46,097 | -38,737 | 0 | 0 | 0 |
Net loss per share attributable to common stockholders, basic and diluted | |||||||||||||
-1.22 | -1.37 | -0.95 | -0.74 | -0.29 | -0.57 | -0.60 | -0.69 | -0.74 | 76.01 | -36.02 | -36.21 | -21.60 | -23.23 |
Weighted average common shares outstanding, basic and diluted: | |||||||||||||
19,557 | 19,094 | 18,659 | 17,667 | 17,221 | 17,790 | 17,471 | 14,376 | 14,369 | 9,347 | 335 | 334 | 330 | 318 |
Comprehensive loss: | |||||||||||||
Net loss | |||||||||||||
-79,111 | -60,925 | -46,538 | -39,284 | -36,090 | -41,662 | -44,931 | -44,312 | -44,119 | -39,886 | 0 | 0 | 0 | - |
Other comprehensive gain (loss): | |||||||||||||
Unrealized gain (loss) on marketable securities | |||||||||||||
-20 | 38 | 35 | 15 | 24 | -28 | 0 | 0 | 0 | - | - | - | - | - |
Reclassification adjustment for gains included in net loss | |||||||||||||
- | -6 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - |
Net unrealized gains (losses) on securities | |||||||||||||
-20 | 44 | 41 | 21 | 30 | -28 | 0 | 0 | 0 | - | - | - | - | - |
Total comprehensive loss | |||||||||||||
-79,131 | -60,881 | -46,497 | -39,263 | -36,060 | -41,690 | -44,954 | -44,327 | -44,148 | -39,886 | 0 | 0 | 0 | - |